跳转至内容
Merck
CN
  • MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17.

MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17.

FEBS letters (2014-05-13)
Yang Wu, Aixue Huang, Tao Li, Xueting Su, Hongmei Ding, Hui Li, Xingliang Qin, Lubin Hou, Qiang Zhao, Xingfeng Ge, Tao Fang, Rong Wang, Changqing Gao, Jie Li, Ningsheng Shao
摘要

As a cleavage enzyme of precursor TNF-α, the high expression level of ADAM17 in endothelial cells is an important factor in atherosclerosis. In this study, we demonstrate that ADAM17 is the target of miR-152. We found that miR-152 could reduce TNF precursor cleavage and inhibit cell proliferation and migration by targeting ADAM17 in human umbilical vein endothelial cells (HUVECs). Furthermore, the expression pattern of miR-152 and corresponding target ADAM17 was opposite in HUVECs under hypoxic conditions. The levels of circulating miR-152 in AS patient sera were lower than those detected in the sera of normal individuals. Our results indicate that miR-152 may be involved in the development of human atherosclerosis and could be used as diagnostic biomarker or therapeutic target in atherosclerosis.

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human ADAM17
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Adam17